Top Markets
#1 0G 0G +34.27%
#2 Nockchain Nockchain +23.06%
#3 Axelar Axelar +21.57%
#4 Fake World Assets Fake World Assets +19.15%
#5 Full Moon Full Moon +17.70%
#6 Zora Zora +17.54%
#7 Merlin's Seal BTC Merlin's Seal BTC +16.09%
#8 Notcoin Notcoin +16.06%
#9 ADO Protocol ADO Protocol +15.57%
#10 StonkBroker StonkBroker +15.35%
Coin of the day
0G 0G
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
Rangering i aksjer #13175
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Aksjekurs
$8.46
Sist synkronisert: 2026-08-28
Markedsverdi
$514.33M
Endring (1 dag)
-2.08%
Endring (1 år)
128.03%
Land
US
Handel Kyverna Therapeutics, Inc. (KYTX)

Kategori

Healthcare
Inntekter for Kyverna Therapeutics, Inc. (KYTX)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Kyverna Therapeutics, Inc. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Kyverna Therapeutics, Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH